Departamento de Química Física e Instituto de Biotecnología, Facultad de Ciencias, Universidad de Granada, 18071 Granada, Spain.
INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
J Mol Biol. 2019 Aug 9;431(17):3091-3106. doi: 10.1016/j.jmb.2019.06.022. Epub 2019 Jun 27.
Development of effective inhibitors of the fusion between HIV-1 and the host cell membrane mediated by gp41 continues to be a grand challenge due to an incomplete understanding of the molecular and mechanistic details of the fusion process. We previously developed single-chain, chimeric proteins (named covNHR) that accurately mimic the N-heptad repeat (NHR) region of gp41 in a highly stable coiled-coil conformation. These molecules bind strongly to peptides derived from the gp41 C-heptad repeat (CHR) and are potent and broad HIV-1 inhibitors. Here, we investigated two covNHR variants differing in two mutations, V10E and Q123R (equivalent to V38E and Q40R in gp41 sequence) that reproduce the effect of HIV-1 mutations associated with resistance to fusion inhibitors, such as T20 (enfuvirtide). A detailed calorimetric analysis of the binding between the covNHR proteins and CHR peptides (C34 and T20) reveals drastic changes in affinity due to the mutations as a result of local changes in interactions at the site of T20 resistance. The crystallographic structure of the covNHR:C34 complex shows a virtually identical CHR-NHR binding interface to that of the post-fusion structure of gp41 and underlines an important role of buried interfacial water molecules in binding affinity and in development of resistance against CHR peptides. Despite the great difference in affinity, both covNHR variants demonstrate strong inhibitory activity for a wide variety of HIV-1 strains. These properties support the high potential of these covNHR proteins as new potent HIV-1 inhibitors. Our results may guide future inhibition approaches.
由于对融合过程的分子和机制细节了解不完整,开发有效抑制 HIV-1 与宿主细胞膜融合的抑制剂仍然是一个巨大的挑战。我们之前开发了一种单链嵌合蛋白(命名为 covNHR),它以高度稳定的卷曲螺旋构象准确模拟了 gp41 的 N 端七肽重复区(NHR)。这些分子与源自 gp41 C 端七肽重复区(CHR)的肽段结合紧密,是有效的广谱 HIV-1 抑制剂。在这里,我们研究了两种 covNHR 变体,它们在两个突变(V10E 和 Q123R,相当于 gp41 序列中的 V38E 和 Q40R)上有所不同,这两个突变复制了与融合抑制剂耐药相关的 HIV-1 突变的效果,如 T20(恩夫韦肽)。对 covNHR 蛋白与 CHR 肽(C34 和 T20)之间结合的详细量热分析表明,由于突变导致亲和力发生了剧烈变化,这是由于 T20 耐药部位相互作用的局部变化所致。covNHR:C34 复合物的晶体结构显示出与 gp41 融合后结构几乎相同的 CHR-NHR 结合界面,并强调了埋藏界面水分子在结合亲和力和对 CHR 肽耐药性发展中的重要作用。尽管亲和力差异很大,但两种 covNHR 变体对多种 HIV-1 株都表现出强烈的抑制活性。这些特性支持这些 covNHR 蛋白作为新型有效的 HIV-1 抑制剂具有很高的潜力。我们的研究结果可能为未来的抑制方法提供指导。